Skip to main content

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More

Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects with Advanced Sarcoma (HEROS)


Sarcomas; refractory HER2-positive sarcoma or metastatic HER2-positive osteosarcoma, not treatable by surgical resection


HER2 is a growth factor receptor that is expressed in many kinds of cancers including some sarcomas. Tumors that express HER2 tend to be more aggressive, so we have developed a chimeric antigen receptor (CAR) to target HER2. In our phase I trial for patients with relapsed or refractory sarcomas (NCT00902044), HER2 CAR T cells are generated from the patient’s own immune cells and are delivered back to the patient in combination with lymphodepletion chemotherapy. The goal of this trial is to determine the safety of HER2 CAR T cells in combination with lymphodepletion chemotherapy and to evaluate whether addition of the chemotherapy improves the anti-tumor response.

Eligibility Criteria

Ages Eligible for Study: Children, Adult

Sexes Eligible for Study: All

Other inclusion and exclusion criteria as listed on



Nabil M. Ahmed, MD  
Principal Investigator

Meenakshi Hegde, MD